• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Continue ACE inhibitors / ARB'S till further evidence in coronavirus disease 2019 (COVID-19).

作者信息

Bansal Sandeep, Agstam Sourabh, Gupta Anunay, Gupta Preeti, Isser H S

机构信息

Department of Cardiology, VMMC and Safdarjung Hospital, New Delhi, India.

出版信息

Indian Heart J. 2020 May-Jun;72(3):212-213. doi: 10.1016/j.ihj.2020.04.007. Epub 2020 May 7.

DOI:10.1016/j.ihj.2020.04.007
PMID:32405087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7218667/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/177b/7411117/161ae8caa089/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/177b/7411117/161ae8caa089/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/177b/7411117/161ae8caa089/gr1.jpg

相似文献

1
Continue ACE inhibitors / ARB'S till further evidence in coronavirus disease 2019 (COVID-19).继续使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂，直至获得更多关于2019冠状病毒病（COVID-19）的证据。
Indian Heart J. 2020 May-Jun;72(3):212-213. doi: 10.1016/j.ihj.2020.04.007. Epub 2020 May 7.
2
The COVID-19 outbreak: a snapshot from down under.新冠疫情：来自南半球的一瞥。
Expert Rev Anticancer Ther. 2020 Jun;20(6):433-436. doi: 10.1080/14737140.2020.1766974. Epub 2020 May 18.
3
[Drugs that aggravate the course of COVID-19 : really ?].[加重新型冠状病毒肺炎病程的药物：真的吗？]
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):852-854.
4
Dermatology staff participate in fight against Covid-19 in China.中国皮肤科医护人员参与抗击新冠疫情。
J Eur Acad Dermatol Venereol. 2020 May;34(5):e210-e211. doi: 10.1111/jdv.16390.
5
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).关于血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂在2019冠状病毒病（COVID-19）中应用的共识声明。
N Z Med J. 2020 Apr 3;133(1512):85-87.
6
Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.新冠疫情期间多发性硬化症患者的康复建议
Arch Iran Med. 2020 Jul 1;23(7):509-510. doi: 10.34172/aim.2020.51.
7
The COVID-19 Outbreak: An Experience for Iranian Health Systems and Orthopedics Association.新冠疫情：伊朗卫生系统与骨科学会的一次经历
Arch Iran Med. 2020 Aug 1;23(8):570-571. doi: 10.34172/aim.2020.63.
8
Covid-19, the pandemic war: Implication for neurologists.新冠疫情：大流行之战对神经科医生的启示
Rev Neurol (Paris). 2020 May;176(4):223-224. doi: 10.1016/j.neurol.2020.03.002.
9
How to Protect Older Adults With Comorbidities During Phase 2 of the COVID-19 Pandemic: Nurses' Contributions.如何在新冠疫情第二阶段保护患有合并症的老年人：护士的贡献
J Gerontol Nurs. 2020 Sep 1;46(9):7-8. doi: 10.3928/00989134-20200811-02.
10
Clinical considerations for patients with diabetes in times of COVID-19 epidemic.2019冠状病毒病疫情期间糖尿病患者的临床考量
Diabetes Metab Syndr. 2020 May-Jun;14(3):211-212. doi: 10.1016/j.dsx.2020.03.002. Epub 2020 Mar 10.

引用本文的文献

1
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention.了解 ACE-2 受体在 COVID-19 疾病发病机制中的作用：一种潜在的治疗干预方法。
Pharmacol Rep. 2021 Dec;73(6):1539-1550. doi: 10.1007/s43440-021-00303-6. Epub 2021 Jun 27.
2
Cardiovascular manifestations of COVID-19: An evidence-based narrative review.COVID-19 的心血管表现：基于证据的叙述性综述。
Indian J Med Res. 2021;153(1 & 2):7-16. doi: 10.4103/ijmr.IJMR_2450_20.
3
Cardiometabolic vigilance in COVID-19 and resource husbandry in resource-challenged times: Clinical practice- based expert opinion.

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
2
SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?严重急性呼吸综合征冠状病毒2：2019冠状病毒病患者是否应停用肾素-血管紧张素系统抑制剂？
Eur Heart J. 2020 May 14;41(19):1801-1803. doi: 10.1093/eurheartj/ehaa235.
3
Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey.
在 COVID-19 期间关注心脏代谢，在资源有限的情况下节约资源：基于临床实践的专家意见。
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):55-62. doi: 10.1016/j.dsx.2020.11.014. Epub 2020 Nov 20.
印度成年人高血压患病率：来自印度大型血压调查的结果
Indian Heart J. 2019 Jul-Aug;71(4):309-313. doi: 10.1016/j.ihj.2019.09.012. Epub 2019 Sep 18.
4
Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.血管紧张素II受体阻滞剂奥美沙坦可能会使高血压患者尿液中的血管紧张素转换酶2增加。
Am J Hypertens. 2015 Jan;28(1):15-21. doi: 10.1093/ajh/hpu086. Epub 2014 May 18.
5
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.联合肾素-血管紧张素系统阻断和血管紧张素转换酶 2 治疗实验性心肌梗死：对未来治疗方向的启示。
Clin Sci (Lond). 2012 Dec;123(11):649-58. doi: 10.1042/CS20120162.
6
Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.奥美沙坦酯治疗通过调节 ACE-2 和 ANG 1-7 mas 受体有力改善心肌肌球蛋白诱导的扩张型心肌病。
Free Radic Res. 2012 Jul;46(7):850-60. doi: 10.3109/10715762.2012.684878. Epub 2012 May 14.
7
Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.奥美沙坦通过调节血管紧张素 1-7 型受体减轻实验性自身免疫性心肌炎大鼠心力衰竭的发展。
Mol Cell Endocrinol. 2012 Apr 4;351(2):208-19. doi: 10.1016/j.mce.2011.12.010. Epub 2011 Dec 19.
8
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.可溶性血管紧张素转换酶 2 在人类心力衰竭中的作用：与心肌功能和临床结局的关系。
J Card Fail. 2009 Sep;15(7):565-71. doi: 10.1016/j.cardfail.2009.01.014. Epub 2009 Mar 17.
9
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.血管紧张素转换酶抑制和血管紧张素II受体阻滞剂对心脏血管紧张素转换酶2的影响。
Circulation. 2005 May 24;111(20):2605-10. doi: 10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
10
Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation.
J Hypertens. 2004 Oct;22(10):1971-6. doi: 10.1097/00004872-200410000-00020.